dc.contributor | Vall d'Hebron Barcelona Hospital Campus |
dc.contributor.author | Piha-Paul, Sarina |
dc.contributor.author | Hann, Christine L. |
dc.contributor.author | French, Christopher A. |
dc.contributor.author | Cousin, Sophie |
dc.contributor.author | Braña Garcia, Irene |
dc.contributor.author | Cassier, Phillippe A. |
dc.date.accessioned | 2021-11-04T14:05:15Z |
dc.date.available | 2021-11-04T14:05:15Z |
dc.date.copyright | 2019 |
dc.date.issued | 2020-04 |
dc.identifier.citation | Piha-Paul SA, Hann CL, French CA, Cousin S, Braña I, Cassier PA, et al. Phase 1 Study of Molibresib (GSK525762), a Bromodomain and Extra-Terminal Domain Protein Inhibitor, in NUT Carcinoma and Other Solid Tumors. JNCI Cancer Spectr. 2020 Apr;4(2):pkz093. |
dc.identifier.issn | 1475-4029 |
dc.identifier.uri | https://hdl.handle.net/11351/6500 |
dc.description | Carcinoma; Concentració de fàrmac en plasma; Farmacocinètica |
dc.description.sponsorship | This study (BET115521; NCT01587703) was supported by GlaxoSmithKline (GSK). Financial support for this work was also provided by National Institutes of Health (NIH) Cancer Center Support Grants P30 CA016672 and P30 CA006516, as well as NIH grant R01 CA124633 to CAF. |
dc.language.iso | eng |
dc.publisher | Published by Oxford University Press |
dc.relation.ispartofseries | JNCI Cancer Spectrum;4(2) |
dc.rights | Attribution-NonCommercial 4.0 International |
dc.rights.uri | http://creativecommons.org/licenses/by-nc/4.0/ |
dc.source | Scientia |
dc.subject | Càncer - Tractament |
dc.subject | Farmacocinètica |
dc.subject.mesh | Carcinoma |
dc.subject.mesh | /drug therapy |
dc.subject.mesh | Antineoplastic Agents |
dc.subject.mesh | /pharmacokinetics |
dc.title | Phase 1 Study of Molibresib (GSK525762), a Bromodomain and Extra-Terminal Domain Protein Inhibitor, in NUT Carcinoma and Other Solid Tumors |
dc.type | info:eu-repo/semantics/article |
dc.identifier.doi | 10.1093/jncics/pkz093 |
dc.subject.decs | carcinoma |
dc.subject.decs | /farmacoterapia |
dc.subject.decs | antineoplásicos |
dc.subject.decs | /farmacocinética |
dc.relation.publishversion | https://doi.org/10.1093/jncics/pkz093 |
dc.type.version | info:eu-repo/semantics/publishedVersion |
dc.audience | Professionals |
dc.contributor.organismes | Institut Català de la Salut |
dc.contributor.authoraffiliation | [Piha-Paul SA] University of Texas MD Anderson Cancer Center, Houston, TX. [Hann CL] Johns Hopkins University School of Medicine, Baltimore, MD. [French CA] Department of Pathology, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA. [Cousin S] Medical Oncology, Institute Bergonié, Bordeaux, France. [Braña I] Servei d’Oncologia Mèdica, Vall d’Hebron Hospital Universitari, Barcelona, Spain. [Cassier PA] Medical Oncology, Léon Bérard Cancer Center, Lyon, France |
dc.identifier.pmid | 32328561 |
dc.identifier.wos | 000608017100016 |
dc.rights.accessrights | info:eu-repo/semantics/openAccess |